Status Complete
Process CG
Topic area
  • Blood and immune system


Key events during the development of the guidance:

Date Update
19 May 2016 - 02 June 2016 Surveillance consultation
16 May 2016 Stakeholder list updated
June 2012 Consultation on the draft of the guideline is complete and the guideline is being modified in the light of comments received.
13 October 2011 The scope defines what aspects of care are covered by the guideline and to whom it applies. Comments that were made by stakeholders during the consultation on the scope can be seen in the scope consultation table.The Guideline Development Group (GDG) oversees the development process.

The Short Clinical Guidelines Technical Team (SCGTT) may make a focussed call for evidence on specific clinical questions or subquestions, after it has done initial searches. It will be able to make a call at any point during development of the guideline, and stakeholders will usually be given 4weeks to respond. The SCGTT will approach all registered stakeholders for this evidence. The SCGTT may not issue any calls for evidence for a guideline if the Guideline Development Group (GDG) feels it is not necessary. In addition, the SCGTT will accept relevant confidential data for consideration by the GDG.

Development of the clinical guideline is under way and is being led by the Shorts Clinical Guidelines Technical Team. The Guideline Development Group meets regularly to oversee and assist the identification, review and synthesis of the evidence, the incorporation of expert consensus opinion and the translation of the evidence into recommendations for practice and audit criteria. Please see timescales above for dates of consultation with stakeholders.
25 March 2010 The remit was received from the Department of Health and the Welsh Assembly Government in February 2010 as part of the Institute's 24th wave work programme.